Publications

5803 Results

A Randomized Study of Temozolomide or Temozolomide and Capecitabine in with Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211)

Authors
P Kunz;P Catalano;H Nimeiri;G Fisher;T Longacre;C Suarez;J Yao;M Kulke;A Hendifar;J Shanks;M Shah;M Zalupski;E Schmulbach;D Reidy-Lagunes;J Strosberg;P O'Dwyer;A Benson
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 4004; ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), oral
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/E2211

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial

Authors
A Bryce;Y Chen;G-F Liu;M Carducci;DF Jarrard;JA Garcia;R Dreicer;M Hussain;MA Eisenberger;M Kohli;NM Hahn;E Plimack;N Vogelzang;J Picus;R DiPaola;L Harshman;C Sweeney
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 5046); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL)
Year
2018
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805

Randomized trial of Irinotecan and Cetuximab (IC) verus Irinotecan, Cetuximab and Ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following Oxaliplatin and Bevacizumab based therapy: Results of E7208

Authors
H Hochster;P Catalano;EP Mitchell;DM Cohen;P O'Dwyer;B Faller;J Kortmansky;M O'Hara;S Kircher;J Lacy;HJ Lenz;U Verma;A Benson
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 3504); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), oral
Year
2018
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/E7208

TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score

Authors
J Sparano;RJ Gray;W Wood;D Makower;T Lively;T Saphner;M Keane;HL Gomez;PS Reddy;T Goggins;I Mayer;D Toppmeyer;A Brufsky;M Goetz;D Hayes;C Dees;K Pritchard;CE Geyer;JA Olson;GW Sledge
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr LBA1); Annual Meeting (June 1- 5, 2018, Chicago, IL)
Year
2018
Research Committee(s)
Breast

Characterization and predictors of long term (= 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients

Authors
M Friedlander;J Chan;J Java;DK Armstrong;M Markman;S Herzog;B Monk;F Backes;A Secord;A Bonebrake;P Rose;K Tewari;RS Mannel;S Lentz;M Geller;LJ Copeland
Journal / Conference
J Clin Oncol 36, 2018 (suppl; abstr 5556); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session
Year
2018
Research Committee(s)
Gynecologic

Dietary fat intake after colon cancer diagnosis in relation to cancer recurrence and survival

Authors
E Van Blarigan;C Fuchs;F-S Ou;D Niedzwiecki;S Zhang;L Saltz;RJ Mayer;A Hantel;A Venook;S Ogino;M Song;E Giovannucci;J Meyerhardt
Journal / Conference
Cancer Epidemiol Biomarkers Prevention Oct;27(10):1227-1230
Year
2018
Research Committee(s)
Gastrointestinal
PMID
PMID30038051
PMC
PMC6170705
Study Number(s)
C89803

Gonadotropin-releasing hormone analogs during chemotherapy for preservation of ovarian function and fertility in premenopausal early breast cancer patients: a systemic review and meta-analysis of individual patient-level data [Review]

Authors
M Lambertini;H Moore;RC Leonard;S Loibl;P Munster;M Bruzzone;L Boni;J Unger;RA Anderson;K Metha;S Minton;F Poggio;K Albain;DJA Adamson;B Gerber;A Cripps;G Bertelli;S Seiler;M Ceppi;A Partridge;L Del Mastro
Journal / Conference
Journal of Clinical Oncology Jul 1;36(19):1981-1990; May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858. [Epub ahead of print]
Year
2018
Research Committee(s)
Breast and Cancer Survivorship
PMID
PMID29718793
PMC
PMC6804855
Study Number(s)
S0230

Rationale, Development, and Design of the Altering Intake, Managing Symptoms (AIMS) Dietary Intervention for Bowel Dysfunction in Rectal Cancer Survivors

Authors
V Sun;T Crane;S Slack;A Yung;S Wright;S Sentovich;K Melstrom;M Fakih;R Krouse
Journal / Conference
Contemporary Clinical Trials May;68:61-66. doi: 10.1016/j.cct.2018.03.010. Epub 2018 Mar 19.
Year
2018
Research Committee(s)
Cancer Survivorship and Symptom Management and Survivorship
PMID
PMID29567283
PMC
PMC5899669

Dietary Modifications for Bowel Dysfunction in Rectal Cancer Survivors: The Altering Intake, Managing Symptoms (AIMS) Intervention Study

Authors
V Sun;TE Crane;S Slack;A Yung;S Wright;S Sentovich;K Melstrom;M Fakih;R Krouse;CA Thomson
Journal / Conference
ASCO Cancer Survivorship Symposium: Advancing Care and Research (February 16-17, 2018, Orlando, FL), abst 141, poster
Year
2018
Research Committee(s)
Cancer Survivorship

Dietary behavior change for bowel symptom management in rectal cancer survivors: the Altering Intake, Managing Symptoms (AIMS) intervention

Authors
V Sun;TE Crane;SD Slack;A Yung;S Wright;R Krouse;CA Thomson
Journal / Conference
ASPO 42nd Annual Conference (Mar 10-13, 2018, New York, NY), poster
Year
2018
Research Committee(s)
Cancer Survivorship